[Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study].
This multicentric study was performed in 494 patients with advanced epithelial ovarian cancer in order to assess the predictive and prognostic value of CA125 half-life and CA125 time to normalization during induction chemotherapy in these patients. For 494 stage IIC-IV patients, 397 relapsed (80.4 %) and 382 died (77.3 %) from cancer during follow time (median = 34 months ; range : 3-215 months). In the population of patients with surgical second look (n = 194), CA125 half-life and normalization before the third cycle were significantly related to pathological complete response by univariate (p < 0,0001) and multivariate (p respectively equal to 0,01 and 0.042) studies. CA 125 half-life and time needed for CA125 normalization had an univariate prognostic value for overall survival (OS) (p < 0.0001 for both). In Cox models, CA 125 half-life (p < 0.0001), residual tumour (p = 0.001), CA125 normalization before the third cycle (p = 0.014) and age (p = 0.032) were independent prognostic factors for OS. Conclusion : Among well-established prognostic factors in ovarian cancers, CA 125 half-life and CA125 time to normalization were independent prognostic factors for both achievement of pathological complete response and survival.
Riedinger
Jean-Marc
JM
Centre Georges-François-Leclerc, 1, rue du Professeur-Marion, 21079 Dijon. jriedinger@dijon.fnclcc.fr
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018394:CA-125 Antigen / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006207:Half-Life; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D011237:Predictive Value of Tests; D011379:Prognosis; D012044:Regression Analysis; D012189:Retrospective Studies; D018709:Statistics, Nonparametric
D018394:CA-125 Antigen